Stock Analiz

4D Molecular Therapeutics, Inc. FDMT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026

$12.23Market cap $690M
Open the interactive analysis →

4D Molecular Therapeutics, Inc. (FDMT) is a healthcare company listed in the US with a market value of about $690M. In the twelve months to September 30, 2026 it had revenue of $96M and net income of -$200M, a net margin of -208.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 44% a year, a 5-year average ROIC of -26%.

About 4D Molecular Therapeutics

4D Molecular Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2020. Revenue went from $7M in 2019 to $85M in 2025, growth of about 51.7% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 79% over three years (dilution for shareholders). It spends 230% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.2
P/B2.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-24.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)230200.0%
Revenue growth (5 yrs, per year)44.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-87856.4%
ROIC (5-yr avg.)-26.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$96M$85M$37000$21M$3M$18M$14M$7M
Net income-$200M-$140M-$161M-$101M-$107M-$71M-$57M-$49M
Free cash flow-$166M-$110M-$138M-$79M-$98M-$78M-$52M-$40M
EPS (diluted)$-2.70$-2.42$-2.98$-2.58$-3.32$-2.57$-8.82$-9.59
Net margin-208.6%-164.4%-434800.0%-486.6%-3435.4%-395.4%-416.5%-705.8%
ROIC—-23.9%-27.7%-27.7%-35.1%-16.8%-17.5%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 11 analysts is $28.09, 130% above the current price; targets range from $18.00 to $37.00; the consensus rating is “Strong buy”; expected EPS is $-4.16 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does 4D Molecular Therapeutics pay a dividend?

Not currently.

Is 4D Molecular Therapeutics a good stock to buy?

We do not give buy or sell advice. 4D Molecular Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.